2026 Dyslipidemia Guidelines: Top 10 Takeaways for CV Risk Reduction

The management of dyslipidemia – abnormal levels of lipids (fats) in the blood – has undergone significant evolution in recent years. The newly released 2026 American College of Cardiology/American Heart Association/Multisociety Guideline on the Management of Dyslipidemia reflects these advances, offering a comprehensive update to improve cardiovascular (CV) health. This guidance arrives at a time of concerning rises in obesity, diabetes, and even myocardial infarction (MI) among young adults, underscoring the need for proactive and personalized approaches to cholesterol management.

The guideline, spanning over 90 pages and incorporating 18 figures and 27 tables, aims to distill the latest evidence into actionable recommendations. Here are 10 key takeaways to guide clinical practice, as highlighted by the writing committee.

Early Detection and Intervention

A central theme of the updated guideline is the importance of “test and treat early.” Recognizing the increasing prevalence of risk factors even in younger populations, the recommendations now include screening with a lipid panel at ages 9 to 11 years, and again between 19 and 21 years. Subsequent screenings should occur at least every five years. This proactive approach, coupled with early health behavior counseling, aims to address modifiable risk factors before they escalate. For young adults exhibiting persistently high LDL cholesterol (at least 160 mg/dL), a strong family history of atherosclerotic cardiovascular disease (ASCVD), or a projected 10-year ASCVD risk of 10% or greater, lipid-lowering therapy should be considered.

The CPR Approach: A Framework for Personalized Risk Assessment

To effectively guide lipid-lowering therapy, the guideline introduces the “CPR” framework: Calculate, Personalize, and Reclassify. First, clinicians should calculate a 10-year ASCVD risk score using the PREVENT equation. This calculation provides a baseline assessment, but it’s crucial to personalize the estimated risk by considering patient-specific risk enhancers. For patients where the decision remains uncertain, coronary artery calcium (CAC) scoring can be used to reclassify risk and refine treatment recommendations.

Understanding PREVENT Thresholds

The PREVENT equations estimate risk for overall CVD, ASCVD, and heart failure. For dyslipidemia management, the PREVENT-ASCVD estimate is most relevant. Lipid-lowering therapy should be considered for primary prevention in adults with an estimated 10-year ASCVD risk between 3% and 5% (borderline risk) who also have risk enhancers, and is recommended for those with a risk between 5% and 10% (intermediate risk).

Reintroducing LDL and Non-HDL Cholesterol Goals

The 2026 guideline re-emphasizes the importance of specific LDL and non-HDL cholesterol goals. Target levels are categorized by risk level: LDL less than 55 mg/dL, less than 70 mg/dL, and less than 100 mg/dL for very high, high, and borderline-intermediate risk, respectively. Corresponding non-HDL goals are less than 85 mg/dL, less than 100 mg/dL, and less than 130 mg/dL – 30 points higher than the LDL goals. These targets provide clear benchmarks for treatment intensification.

The Role of Apolipoprotein B

Once LDL and non-HDL levels are approaching goal, particularly in patients with high triglycerides or diabetes, measuring apolipoprotein B (ApoB) can help guide further treatment decisions. ApoB goals align with risk levels: less than 55 mg/dL, less than 70 mg/dL, and less than 90 mg/dL for very high, high, and borderline-intermediate risk patients, respectively.

Lipoprotein(a): A Genetically Driven Risk Factor

Lipoprotein(a) [Lp(a)] is a highly atherogenic lipoprotein with levels largely determined by genetics. The guideline recommends checking Lp(a) at least once in every patient’s lifetime to inform intensified preventive efforts. Levels at or above 125 nmol/L are considered risk enhancers, associated with a 1.4-fold increased ASCVD risk, while levels of 250 nmol/L or higher are linked to more than a twofold increase in risk.

Coronary Artery Calcium Scoring for Risk Refinement

CAC scoring, a safe and affordable imaging technique, can provide valuable insights into atherosclerotic risk. It’s recommended for men aged 40 years or older and women aged 45 years or older, particularly when lipid-lowering decision-making is uncertain. Both the absolute CAC score and its standardized percentile should be considered when interpreting the results.

Primary Prevention in Specific Populations

Adults aged 40 to 75 years with diabetes, chronic kidney disease (stages 3-4), or HIV should receive lipid-lowering therapy regardless of their LDL level. The benefits of LDL lowering also extend to older adults (over 75) with dyslipidemia. Lifestyle optimization and shared decision-making remain crucial components of healthy cardiovascular aging.

Secondary Prevention: Lower is Better

For patients with established ASCVD, an LDL goal of less than 55 mg/dL is recommended, especially for those at very high risk (two or more major ASCVD events, or one event plus two high-risk conditions). The guideline emphasizes that “the lower the LDL, the better.” Treatment should begin with a maximally tolerated statin, followed by the addition of ezetimibe, bempedoic acid (Nexletol), and/or a PCSK9 inhibitor, with inclisiran (Leqvio) considered for further LDL reduction.

Managing Hypertriglyceridemia

Triglyceride levels of 150 mg/dL or higher are associated with increased ASCVD risk and are often responsive to lifestyle interventions. Statins remain the foundation of pharmacotherapy for elevated triglycerides. For more substantial reductions, fenofibrate and icosapent ethyl should be considered. In cases of familial chylomicronemia syndrome, apolipoprotein C3 inhibitors may be appropriate.

Implementing these recommendations, alongside the broader guidance detailed in the 2026 ACC/AHA/Multisociety Dyslipidemia Guideline, will be essential to improving heart health across all populations and life stages. The evolving understanding of lipid metabolism and its impact on cardiovascular disease necessitates a continuous commitment to evidence-based care and personalized treatment strategies.

For more information: Aaron L. Troy, MD, MPH, Seth S. Martin, MD, MHS, and Roger S. Blumenthal, MD, were all involved in the writing of this guideline.